Article Versions Notes

Barutello G, Di Lorenzo A, Gasparetto A, Galiazzi C, Bolli E, Conti L, Cavallo F. Immunotherapy against the Cystine/Glutamate Antiporter xCT Improves the Efficacy of APR-246 in Preclinical Breast Cancer Models. Biomedicines. 2022; 10(11):2843. https://doi.org/10.3390/biomedicines10112843

Barutello, Giuseppina, Antonino Di Lorenzo, Alessandro Gasparetto, Chiara Galiazzi, Elisabetta Bolli, Laura Conti, and Federica Cavallo. 2022. "Immunotherapy against the Cystine/Glutamate Antiporter xCT Improves the Efficacy of APR-246 in Preclinical Breast Cancer Models" Biomedicines 10, no. 11: 2843. https://doi.org/10.3390/biomedicines10112843

Barutello, G., Di Lorenzo, A., Gasparetto, A., Galiazzi, C., Bolli, E., Conti, L., & Cavallo, F. (2022). Immunotherapy against the Cystine/Glutamate Antiporter xCT Improves the Efficacy of APR-246 in Preclinical Breast Cancer Models. Biomedicines, 10(11), 2843. https://doi.org/10.3390/biomedicines10112843